Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the sale, the director now directly owns 33,514 shares in the company, valued at approximately $1,248,396.50. The trade was a 35.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Exelixis Price Performance
Shares of NASDAQ EXEL opened at $37.53 on Thursday. The stock's 50-day moving average is $34.34 and its two-hundred day moving average is $31.50. The company has a market cap of $10.50 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $37.64.
Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. Truist Financial lifted their target price on Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a research report on Monday, January 27th. UBS Group boosted their price objective on shares of Exelixis from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Wells Fargo & Company lowered shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price for the company. in a research note on Monday. Brookline Capital Management began coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a "buy" rating for the company. Finally, Guggenheim restated a "buy" rating and issued a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.24.
View Our Latest Analysis on Exelixis
Institutional Investors Weigh In On Exelixis
Institutional investors have recently modified their holdings of the company. Seizert Capital Partners LLC lifted its holdings in Exelixis by 8.0% during the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company's stock worth $12,195,000 after buying an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock worth $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in Exelixis in the third quarter valued at approximately $4,396,000. China Universal Asset Management Co. Ltd. increased its stake in Exelixis by 60.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company's stock valued at $1,424,000 after purchasing an additional 20,641 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in Exelixis during the third quarter worth approximately $577,000. 85.27% of the stock is owned by hedge funds and other institutional investors.
About Exelixis
(
Get Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
